US equities
|
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
AngioDynamics, Inc. - Common Stock
(NQ:
ANGO
)
11.23
-2.96 (-20.86%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AngioDynamics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Why AngioDynamics Crashed Today
↗
Today 11:11 EDT
AngioDynamics beats earnings, and drops 20%.
Via
The Motley Fool
Traders are paying attention to the gapping stocks in Thursday's session.
↗
Today 10:30 EDT
Via
Chartmill
AngioDynamics Q1 Earnings Call Highlights
↗
Today 10:02 EDT
AngioDynamics (NASDAQ:ANGO) reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year...
Via
MarketBeat
Topics
Earnings
AngioDynamics (NASDAQ:ANGO) Posts Narrower Q1 Loss, Holds Guidance Below Consensus
↗
Today 7:20 EDT
Via
Chartmill
AngioDynamics (NASDAQ:ANGO) Surges on Strong Quarterly Beat as Med Tech Segment Drives Growth
↗
July 14, 2026
Via
Chartmill
AngioDynamics Inc (NASDAQ:ANGO) Beats Q3 Earnings Estimates and Raises Full-Year Guidance
↗
April 02, 2026
Via
Chartmill
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
Today 6:02 EDT
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
Today 6:00 EDT
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
October 02, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
September 28, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
↗
August 11, 2026
AngioDynamics (NASDAQ:ANGO) expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and...
Via
MarketBeat
AngioDynamics to Participate in Upcoming Investor Conferences
July 28, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript
↗
July 21, 2026
Med Tech revenue surged 16.7% as company shifts toward higher-margin products.
Via
The Motley Fool
Topics
Earnings
World Trade
AngioDynamics Q4 Earnings Call Highlights
↗
July 14, 2026
AngioDynamics (NASDAQ:ANGO) reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on...
Via
MarketBeat
Topics
Earnings
Full Transcript: AngioDynamics Q4 2026 Earnings Call
↗
July 14, 2026
AngioDynamics (NASDAQ:ANGO) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered by Benzinga APIs. For...
Via
Benzinga
Topics
Earnings
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
July 14, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
June 30, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
June 17, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
May 28, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
May 13, 2026
From
AngioDynamics, Inc.
Via
Business Wire
Med-Tech Resilience: AngioDynamics Pivot Pays Off with Double-Digit Growth and Profitability
April 02, 2026
The medical technology sector has long been a bellwether for the health of the broader economy and the efficiency of the healthcare system. Today, April 2, 2026, AngioDynamics (NASDAQ:ANGO) provided...
Via
MarketMinute
Topics
Economy
Retirement
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
April 02, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
March 31, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
March 19, 2026
From
AngioDynamics, Inc.
Via
Business Wire
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
↗
February 27, 2026
Parsons delivers technology-driven solutions for defense, intelligence, and critical infrastructure clients across North America and beyond.
Via
The Motley Fool
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
February 23, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
February 19, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
February 05, 2026
From
AngioDynamics, Inc.
Via
Business Wire
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
February 03, 2026
From
AngioDynamics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
